When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Gliomas

Evidence last reviewed: 11 Jun 2026
Topic last updated: 30 Jun 2026

Summary

Definition

History and exam

Key diagnostic factors

  • fatigue
Full details

Other diagnostic factors

  • altered mental status
  • headache
  • nausea and/or vomiting
  • gait abnormality
  • ataxia
  • weakness
  • seizures
  • visual disturbances
  • speech deficit
  • aphasia/dysphasia
  • sensory deficit
  • motor weakness
  • visual change
  • cranial nerve palsy
  • papilledema
  • personality change/emotional lability
Full details

Risk factors

  • white ancestry
  • male sex
  • neurofibromatosis type 1
  • tuberous sclerosis complex
  • Li-Fraumeni syndrome
  • Turcot syndrome
  • ionizing radiation
Full details

Diagnostic tests

1st tests to order

  • MRI head
  • ophthalmologic evaluation; visual field testing
  • CT head
  • brain MR spectroscopy
  • brain perfusion MRI
  • histopathology
  • molecular analyses
Full details

Tests to consider

  • pituitary hormones tests
  • diffusion tensor imaging (DTI)
Full details

Emerging tests

  • 2-hydroxyglutarate-targeted magnetic resonance spectroscopy
  • amino acid PET
  • cerebrospinal fluid liquid biopsy

Treatment algorithm

ACUTE

circumscribed glioma: pediatric low-grade gliomas including pilocytic astrocytoma

circumscribed glioma: subependymal giant cell astrocytoma (grade 1)

circumscribed glioma: pleomorphic xanthoastrocytoma

diffuse infiltrating glioma: grade 2 and accessible

diffuse infiltrating glioma: grade 2 and inaccessible

high-grade diffuse infiltrating glioma

diffuse midline glioma, H3 K27M-altered, grade 4

ONGOING

recurrent circumscribed glioma

progressive diffuse infiltrating glioma

Contributors

Authors

Douglas E. Ney, MD

Director of Medical Neuro-Oncology

Cottage Health Neurosciences

Santa Barbara, CA

Disclosures

DEN declares that he has no competing interests.

Acknowledgements

Dr Douglas E. Ney would like to gratefully acknowledge Dr L. Nicolas Gonzalez Castro, Dr Timothy C. Ryken, Dr Linton T. Evans, Dr Manmeet S. Ahluwalia, Dr Susan Chang, and Dr Karine Michaud, previous contributors to this topic.

Disclosures

LNGC has received consulting fees from Elsevier, Oakstone Publishing, and Teladoc. LNGC has received research funding from Merck & Co. (to Dana-Farber Cancer Institute). LNGC is an author of a number of references cited in this topic. TCR is an author of a number of references cited in this topic. MSA has acted as a consultant for Elekta, Incyte, AstraZeneca, Novocure, Caris Life Sciences, Bristol-Myers Squibb, Monteris Medical, AbbVie, MRI Solutions, Elsevier, and Prime oncology. MSA has received clinical trial investigations grants from Tracon, Bristol-Myers Squibb, AstraZeneca, Novartis, and Novocure. SC has received research support from Agios, Novartis, Quest, Roche, and Schering Plough. KM and LTE declare that they have no competing interests.

Peer reviewers

David A. Reardon, MD

Associate Professor

The Preston Robert Tisch Brain Tumor Center

Duke University Medical Center

Durham, NC

Disclosures

DAR declares that he has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021 Aug 2;23(8):1231-51.Full text  Abstract

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: central nervous system cancers [internet publication].Full text

European Association of Neuro-Oncology. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. 2021 [internet publication].Full text

Wen PY, Weller M, Lee EQ, et al. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2025 Nov 1;27(11):2751-88.Full text  Abstract

American Society of Clinical Oncology; Society for Neuro-Oncology. Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline. 2022 [internet publication].Full text

American Association of Neurological Surgeons; Congress of Neurological Surgeons. Updated AANS/CNS guidelines for progressive glioblastoma patients. Jun 2022 [internet publication].Full text

Reference articles

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
  • Gliomas images
  • Differentials

    • Brain metastasis
    • Brain abscess
    • Multiple sclerosis
    More Differentials
  • Guidelines

    • NCCN clinical practice guidelines in oncology: central nervous system cancers
    • Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline
    More Guidelines
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer